Literature DB >> 23331974

Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?

L Myatt1, R G Clifton, J M Roberts, C Y Spong, R J Wapner, J M Thorp, B M Mercer, A M Peaceman, S M Ramin, M W Carpenter, A Sciscione, J E Tolosa, G Saade, Y Sorokin, G D Anderson.   

Abstract

OBJECTIVE: To determine if change in maternal angiogenic biomarkers between the first and second trimesters predicts pre-eclampsia in low-risk nulliparous women.
DESIGN: A nested case-control study of change in maternal plasma soluble Flt-1 (sFlt-1), soluble endoglin (sEng) and placenta growth factor (PlGF). We studied 158 pregnancies complicated by pre-eclampsia and 468 normotensive nonproteinuric controls.
SETTING: A multicentre study in 16 academic medical centres in the USA. POPULATION: Low-risk nulliparous women.
METHODS: Luminex assays for PlGF, sFlt-1 and sEng performed on maternal EDTA plasma collected at 9-12, 15-18 and 23-26 weeks of gestation. Rate of change of analyte between first and either early or late second trimester was calculated with and without adjustment for baseline clinical characteristics. MAIN OUTCOME MEASURES: Change in PlGF, sFlt-1 and sEng.
RESULTS: Rates of change of PlGF, sEng and sFlt-1 between first and either early or late second trimesters were significantly different in women who developed pre-eclampsia, severe pre-eclampsia or early-onset pre-eclampsia compared with women who remained normotensive. Inclusion of clinical characteristics (race, body mass index and blood pressure at entry) increased sensitivity for detecting severe and particularly early-onset pre-eclampsia but not pre-eclampsia overall. Receiver operating characteristics curves for change from first to early second trimester in sEng, PlGF and sFlt-1 with clinical characteristics had areas under the curve of 0.88, 0.84 and 0.86, respectively, and for early-onset pre-eclampsia with sensitivities of 88% (95% CI 64-99), 77% (95% CI 50-93) and 77% (95% CI 50-93) for 80% specificity, respectively. Similar results were seen in the change from first to late second trimester.
CONCLUSION: Change in angiogenic biomarkers between first and early second trimester combined with clinical characteristics has strong utility for predicting early-onset pre-eclampsia. © Published 2013 This article is a U.S. Government work and is in the public domain in the USA
© 2013 RCOG.

Entities:  

Keywords:  Angiogenesis; endoglin; platelet growth factor; pre-eclampsia; sFlt-1

Mesh:

Substances:

Year:  2013        PMID: 23331974      PMCID: PMC4104359          DOI: 10.1111/1471-0528.12128

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  19 in total

1.  Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia.

Authors:  Lars J Vatten; Anne Eskild; Tom I L Nilsen; Stig Jeansson; Pål A Jenum; Anne Cathrine Staff
Journal:  Am J Obstet Gynecol       Date:  2007-03       Impact factor: 8.661

2.  Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic.

Authors:  M Ziche; D Maglione; D Ribatti; L Morbidelli; C T Lago; M Battisti; I Paoletti; A Barra; M Tucci; G Parise; V Vincenti; H J Granger; G Viglietto; M G Persico
Journal:  Lab Invest       Date:  1997-04       Impact factor: 5.662

3.  Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.

Authors:  Jennie Laigaard; Tina Sørensen; Sophie Placing; Peter Holck; Camilla Fröhlich; Karen R Wøjdemann; Karin Sundberg; Anne-Cathrine Shalmi; Ann Tabor; Bent Nørgaard-Pedersen; Bent Ottesen; Michael Christiansen; Ulla M Wewer
Journal:  Obstet Gynecol       Date:  2005-07       Impact factor: 7.661

4.  Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.

Authors:  S Caritis; B Sibai; J Hauth; M D Lindheimer; M Klebanoff; E Thom; P VanDorsten; M Landon; R Paul; M Miodovnik; P Meis; G Thurnau
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

5.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Authors:  Richard J Levine; Chun Lam; Cong Qian; Kai F Yu; Sharon E Maynard; Benjamin P Sachs; Baha M Sibai; Franklin H Epstein; Roberto Romero; Ravi Thadhani; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

6.  Localisation of placenta growth factor (PIGF) in human term placenta.

Authors:  A Khaliq; X F Li; M Shams; P Sisi; C A Acevedo; M J Whittle; H Weich; A Ahmed
Journal:  Growth Factors       Date:  1996       Impact factor: 2.511

7.  Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia.

Authors:  S C Tidwell; H N Ho; W H Chiu; R J Torry; D S Torry
Journal:  Am J Obstet Gynecol       Date:  2001-05       Impact factor: 8.661

8.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation.

Authors:  D E Clark; S K Smith; D Licence; A L Evans; D S Charnock-Jones
Journal:  J Endocrinol       Date:  1998-12       Impact factor: 4.286

10.  Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial.

Authors: 
Journal:  Lancet       Date:  1995-06-10       Impact factor: 79.321

View more
  28 in total

1.  The association between prenatal alcohol exposure and protein expression in human placenta.

Authors:  Bradley D Holbrook; Suzy Davies; Sandra Cano; Shikhar Shrestha; Lauren L Jantzie; William F Rayburn; Ludmila N Bakhireva; Daniel D Savage
Journal:  Birth Defects Res       Date:  2019-03-19       Impact factor: 2.344

2.  Choroidal and retinal thickening in severe preeclampsia.

Authors:  Aakriti Garg; Ronald J Wapner; Cande V Ananth; Elizabeth Dale; Stephen H Tsang; Winston Lee; Rando Allikmets; Srilaxmi Bearelly
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-29       Impact factor: 4.799

3.  Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Authors:  Nandor Gabor Than; Roberto Romero; Adi Laurentiu Tarca; Katalin Adrienna Kekesi; Yi Xu; Zhonghui Xu; Kata Juhasz; Gaurav Bhatti; Ron Joshua Leavitt; Zsolt Gelencser; Janos Palhalmi; Tzu Hung Chung; Balazs Andras Gyorffy; Laszlo Orosz; Amanda Demeter; Anett Szecsi; Eva Hunyadi-Gulyas; Zsuzsanna Darula; Attila Simor; Katalin Eder; Szilvia Szabo; Vanessa Topping; Haidy El-Azzamy; Christopher LaJeunesse; Andrea Balogh; Gabor Szalai; Susan Land; Olga Torok; Zhong Dong; Ilona Kovalszky; Andras Falus; Hamutal Meiri; Sorin Draghici; Sonia S Hassan; Tinnakorn Chaiworapongsa; Manuel Krispin; Martin Knöfler; Offer Erez; Graham J Burton; Chong Jai Kim; Gabor Juhasz; Zoltan Papp
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

4.  Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD).

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; James H Segars; Alan H DeCherney; M Cathleen McCoy; Chong Jai Kim; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2015-04-20

Review 5.  Prediction of preeclampsia-bench to bedside.

Authors:  Anjali Acharya; Wunnie Brima; Shivakanth Burugu; Tanvi Rege
Journal:  Curr Hypertens Rep       Date:  2014-11       Impact factor: 5.369

6.  Maternal circulating angiogenic factors in twin and singleton pregnancies.

Authors:  Jessica M Faupel-Badger; Thomas F McElrath; Michele Lauria; Lauren C Houghton; Kee-Hak Lim; Samuel Parry; David Cantonwine; Gabriel Lai; S Ananth Karumanchi; Robert N Hoover; Rebecca Troisi
Journal:  Am J Obstet Gynecol       Date:  2014-11-27       Impact factor: 8.661

7.  Associating Symptom Phenotype and Genotype in Preeclampsia.

Authors:  Sandra A Founds; Eleni Tsigas; Dianxu Ren; M Michael Barmada
Journal:  Biol Res Nurs       Date:  2018-01-22       Impact factor: 2.522

8.  Combination of serum angiopoietin-2 and uterine artery Doppler for prediction of preeclampsia.

Authors:  Ploynin Puttapitakpong; Vorapong Phupong
Journal:  Hypertens Res       Date:  2015-10-22       Impact factor: 3.872

Review 9.  Preeclampsia and Vascular Function: A Window to Future Cardiovascular Disease Risk.

Authors:  Davaasambuu Enkhmaa; Danielle Wall; Puja K Mehta; Jennifer J Stuart; Janet Wilson Rich-Edwards; C Noel Bairey Merz; Chrisandra Shufelt
Journal:  J Womens Health (Larchmt)       Date:  2016-01-18       Impact factor: 2.681

Review 10.  Pre-eclampsia part 2: prediction, prevention and management.

Authors:  Tinnakorn Chaiworapongsa; Piya Chaemsaithong; Steven J Korzeniewski; Lami Yeo; Roberto Romero
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.